Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nemonoxacin - TaiGen Biotechnology

Drug Profile

Nemonoxacin - TaiGen Biotechnology

Alternative Names: Nemonoxacin malate sodium chloride; Taigexyn; TG-873870

Latest Information Update: 15 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Procter & Gamble
  • Developer R-Pharm; TaiGen Biotechnology; Zhejiang Medicine
  • Class Antibacterials; Piperidines; Quinolones; Small molecules
  • Mechanism of Action DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Community-acquired pneumonia
  • Phase II Diabetic foot ulcer
  • Phase I Kidney disorders
  • Phase Unknown Skin and soft tissue infections

Most Recent Events

  • 05 Feb 2018 The Chinese FDA grants priority review to nemonoxacin for Community-acquired pneumonia
  • 15 Jan 2018 ZheJiang Medicine completes a phase I trial in Volunteers with impaired hepatic function in China (NCT02604498)
  • 30 May 2017 Preregistration for Community-acquired pneumonia in China (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top